Patents Assigned to Bayer Schering Pharma AG
  • Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments
    Patent number: 7750000
    Abstract: The invention relates to novel inhibitors of kinases, and pharmaceutical compositions comprising them. The inhibitors are substituted imidazo[1,2b]pyridazines.
    Type: Grant
    Filed: September 1, 2006
    Date of Patent: July 6, 2010
    Assignee: Bayer Schering Pharma AG
    Inventors: Olaf Prien, Stuart James Ince, Knut Eis, Christoph Huwe, Ulrich Lücking, Rolf Jautelat, Ulrich Zügel, Judith Günther, Benjamin Bader, Manfred Husemann, Karina Schuck
  • Oxazolidinone For The Treatment And Prophylaxis Of Pulmonary Hypertension
    Publication number: 20100144728
    Abstract: The present invention relates to the use of factor Xa inhibitors, especially of oxazolidinones of the formula (I), for the treatment and/or prophylaxis of pulmonary hypertension, and to the use thereof for the manufacture of medicaments for the treatment and/or prophylaxis of pulmonary hypertension.
    Type: Application
    Filed: April 10, 2008
    Publication date: June 10, 2010
    Applicant: Bayer Schering Pharma AG
    Inventors: Georges Von Degenfeld, Martina Klein, Elisabeth Perzborn, Joachim Hütter, Gerrit Weimann
  • Depth stop devices and systems
    Patent number: 7730628
    Abstract: A depth stop device for use in connection with another device or apparatus (for example, a medical device) includes a stop member slidably positionable on the device, at least one abutment member in operative connection with the stop member to adjustably contact the device to lock the stop member in a desired position relative to the device or to free the stop member to slide relative to the device, and an adjustment member connected to the abutment member to control a position of the abutment member relative to the device. The force applicable by the abutment member to the device is limited to be less than a certain force.
    Type: Grant
    Filed: September 5, 2008
    Date of Patent: June 8, 2010
    Assignee: Bayer Schering Pharma AG
    Inventor: Raymond C. Hoffman
  • GENERATION OF ONCOLYTIC ADENOVIRUSES AND USES THEREOF
    Publication number: 20100136658
    Abstract: The present invention relates to a method for the production of onolytic adenoviruses having increased potency and their therapeutic applications for cancer. Recombinant adenoviruses and methods to produce them are provided.
    Type: Application
    Filed: December 20, 2007
    Publication date: June 3, 2010
    Applicant: BAYER SCHERING PHARMA AG
    Inventors: Terry Hermiston, Irene KUHN
  • SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION
    Publication number: 20100137274
    Abstract: The invention relates to the field of blood coagulation. Novel oxazolidinone derivatives of the general formula (I) processes for their preparation and their use as medicinally active compounds for the prophylaxis and/or treatment of disorders are described.
    Type: Application
    Filed: June 30, 2009
    Publication date: June 3, 2010
    Applicant: Bayer Schering Pharma AG
    Inventors: Alexander Straub, Thomas Lampe, Jens Pohlmann, Susanne Rohrig, Elisabeth Perzborn, Karl-Heinz Schlemmer, Joseph Pernerstorfer
  • Process for recovery of iopromide, suitable for pharmaceutical purposes, from mother liquors
    Patent number: 7723544
    Abstract: This invention describes a process for recovery of iopromide, suitable for pharmaceutical purposes, by heat treatment of the mother liquors or the secondary crystallizate in a reactor and subsequent crystallization.
    Type: Grant
    Filed: December 4, 2006
    Date of Patent: May 25, 2010
    Assignee: Bayer Schering Pharma AG
    Inventors: Hartmut Kagerer, Meike Dembeck, Hartmut Seba, Ingo Ortmann
  • Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels
    Patent number: 7718640
    Abstract: The present invention relates to pharmaceutical compositions, formulated for injectable administration, which comprises a testosterone ester, in particularly testosterone undecanoate, in a vehicle comprising castor oil and a co-solvent. Upon injecting the compositions according to a particular administration scheme, reliable levels of testosterone in serum in the normal physiological range is achieved for a long period. This allows for the use of the compositions in hormone replacement therapy and male contraception without concomitant monitoring of testosterone levels in serum by a physician.
    Type: Grant
    Filed: March 12, 2004
    Date of Patent: May 18, 2010
    Assignee: Bayer-Schering Pharma AG
    Inventors: Doris Hubler, Sabine Fricke, Jan-Peter Ingwersen, Wilhelm Kuhnz
  • Sustained-release preparations of quinolone antibiotics and method for preparation thereof
    Patent number: 7709022
    Abstract: The present invention relates to an orally administrable preparation comprising a quinolone antibiotic which releases the active compound with a delay.
    Type: Grant
    Filed: June 13, 2001
    Date of Patent: May 4, 2010
    Assignee: Bayer Schering Pharma AG
    Inventors: Venkata-Rangarao Kanikanti, Roland Rupp, Wolfgang Weber, Peter Deuringer, Jan-Olav Henck, Heino Staβ, Takaaki Nishioka, Yoshifumi Katakawa, Chika Taniguchi, Hitoshi Ichihashi
  • Regulation of Human Transmembrane Serine Protease
    Publication number: 20100069615
    Abstract: Reagents that regulate human transmembrane serine protease activity and reagents that bind to human transmembrane serine protease gene products can be used to regulate extracellular matrix degradation. Such regulation is particularly useful for treating COPD, metastasis of malignant cells, tumor angiogenesis, inflammation, atherosclerosis, neurodegenerative diseases, and pathogenic infections.
    Type: Application
    Filed: October 15, 2009
    Publication date: March 18, 2010
    Applicant: BAYER SCHERING PHARMA AG
    Inventors: Yonghong Xiao, Richard W. Gedrich
  • N-(2-Aminophenyl)-4-[N-(Pyridine-3-yl)-Methoxycarbonyl-Aminomethyl]-Benzamide (MS-275) Polymorph B
    Publication number: 20100056585
    Abstract: The crystalline Polymorph B of N-(2-aminophenyl)-4-[N-(pyridine-3-yl)methoxy-carbonyaminomethyl]benzamide (MS-275) of formula I is described, as well as the process for the production of said compound, and its use as a medicament for the treatment of selected diseases.
    Type: Application
    Filed: August 28, 2009
    Publication date: March 4, 2010
    Applicant: BAYER SCHERING PHARMA AG
    Inventors: Matthias Schneider, Michael Gottfried, Jens Geisler, Gabriele Winter
  • Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
    Patent number: 7662821
    Abstract: The invention relates to tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents.
    Type: Grant
    Filed: October 12, 2004
    Date of Patent: February 16, 2010
    Assignee: Bayer Schering Pharma AG
    Inventors: Hartmut Rehwinkel, Stefan Baeurle, Markus Berger, Norbert Schmees, Heike Schaecke, Konrad Krolikiewicz, Anne Mengel, Duy Nguyen, Stefan Jaroch, Werner Skuballa
  • Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
    Patent number: 7659297
    Abstract: The invention relates to multiply-substituted tetrahydronaphthalene derivatives of formula (I) process for their production and their use as antiinflammatory agents.
    Type: Grant
    Filed: October 8, 2004
    Date of Patent: February 9, 2010
    Assignee: Bayer Schering Pharma, AG
    Inventors: Hartmut Rehwinkel, Stefan Baeurle, Markus Berger, Norbert Schmees, Heike Schaecke, Konrad Krolikiewicz, Anne Mengel, Duy Nguyen, Stefan Jaroch, Werner Skuballa
  • Extended Benzamide Derivatives as Modulators of the EP2 Receptor
    Publication number: 20100029598
    Abstract: The present invention relates to extended benzamide derivatives of the general formula I, to processes for preparation thereof and to use thereof for production of pharmaceutical compositions for treatment of disorders and indications associated with the EP2 receptor.
    Type: Application
    Filed: July 24, 2009
    Publication date: February 4, 2010
    Applicant: Bayer Schering Pharma AG
    Inventors: Marcus Kopitz, Bernhard Lindenthal, Antonius Ter Laak, Tim Wintermantel, Olaf Peters, Gernot Langer, Nico Braeuer, Bernd Buchmann
  • Optically active, heteroaromatic ?-hydroxy esters and processes for their preparation from ?-keto esters and processes for the preparation of these ?-keto esters
    Patent number: 7626035
    Abstract: The present invention relates to new optically active heteroaromatic ?-hydroxy esters useful in the synthesis of epothilone derivatives, to certain compounds used to produce these intermediates, as well as to processes for their production.
    Type: Grant
    Filed: January 3, 2005
    Date of Patent: December 1, 2009
    Assignee: Bayer Schering Pharma AG
    Inventors: Johannes Platzek, Ludwig Zorn, Bernd Buchmann, Werner Skuballa, Orlin Petrov
  • Regulation of human transmembrane serine protease
    Patent number: 7622292
    Abstract: Reagents that regulate human transmembrane serine protease activity and reagents that bind to human transmembrane serine protease gene products can be used to regulate extracellular matrix degradation. Such regulation is particularly useful for treating COPD, metastasis of malignant cells, tumor angiogenesis, inflammation, atherosclerosis, neurodegenerative diseases, and pathogenic infections.
    Type: Grant
    Filed: November 7, 2007
    Date of Patent: November 24, 2009
    Assignee: Bayer Schering Pharma AG
    Inventors: Xiao Yonghong, Richard W. Gedrich
  • USE OF A VIRUS REGIMEN FOR THE TREATMENT OF DISEASES
    Publication number: 20090280122
    Abstract: The use of a virus regimen, especially an oncolytic regimen for the production of a medicament for the treatment of a disease, especially cancer is described. The virus regimen is applied after reducing, shutting down or modifying functioning of the immune system in a controlled manner. In a preferred embodiment T-cell depletion or T-cell modification is used for controlling the immune system. The T-cell depletor or T-cell modifier is administered either separately or as part of the virotherapy regimen.
    Type: Application
    Filed: May 8, 2009
    Publication date: November 12, 2009
    Applicant: BAYER SCHERING PHARMA AG
    Inventor: Werner KRAUSE
  • Effector conjugates, methods for their preparation and their pharmaceutical use
    Patent number: 7605136
    Abstract: Conjugates of epothilones and epothilone derivatives (as effectors) with suitable saccharides or saccharide derivatives (as recognition units) are described. Their production is carried out by the recognition units being reacted with suitable linkers, and the compounds that are produced are conjugated to the effectors. The pharmaceutical use of the conjugates for treating proliferative or angiogenesis-associated processes is described.
    Type: Grant
    Filed: December 5, 2003
    Date of Patent: October 20, 2009
    Assignee: Bayer Schering Pharma AG
    Inventors: Klaus Bosslet, Holger Hess-Stumpp, Jens Hoffmann, Ulrich Klar, Andrea Rotgeri
  • Anti-androgenic pyrrolidines with tumor-inhibiting action
    Patent number: 7601748
    Abstract: This invention relates to anti-androgenic N-[?-[3-[4-cyano-3-(trifluoromethyl)-phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]alkyl]-substituted pyrrolidines of general formula I, with a strongly pronounced antiproliferative profile of action; process for the production of the compounds of general formula I, pharmaceutical preparations and the use for the production of pharmaceutical agents.
    Type: Grant
    Filed: August 9, 2006
    Date of Patent: October 13, 2009
    Assignee: Bayer Schering Pharma AG
    Inventors: Arwed Cleve, Volker Schulze, Dieter Zopf, Jens Hoffmann, Andreas Reichel, Karsten Parczyk
  • Cyanoquinoline derivatives, their preparation, their use, and medicaments comprising them
    Patent number: 7598263
    Abstract: The present invention relates to a quinoline derivative having the general formula (A): in which R1, R2, X, Y and Z are indicated in the description and the claims, the use of the compounds of the general formula (A) for the treatment of various disorders, and the preparation of compounds of the general formula (A).
    Type: Grant
    Filed: June 20, 2007
    Date of Patent: October 6, 2009
    Assignee: Bayer Schering Pharma AG
    Inventors: Olaf Prien, Knut Eis, Wolfgang Schwede, Judith Guenther, Dieter Zopf
  • Portion of a display screen for a pill dispenser
    Patent number: D618904
    Type: Grant
    Filed: June 23, 2009
    Date of Patent: July 6, 2010
    Assignee: Bayer Schering Pharma AG
    Inventors: Sabine Leifeld, Heike Ranze, Parviz Bazargani